Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Cardiol. May 26, 2026; 18(5): 119863
Published online May 26, 2026. doi: 10.4330/wjc.v18.i5.119863
Published online May 26, 2026. doi: 10.4330/wjc.v18.i5.119863
Systematic review and meta-analysis of prognostic markers in transthyretin amyloid cardiomyopathy
Tarun Dalia, Joseph Mancuso, Zubair Shah, Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas, KS 66160, United States
Varun Kohli, Department of Cardiovascular Medicine, University of Nevada, Reno and Carson Tahoe Medical Group, Reno, NV 89557, United States
Amandeep Goyal, Department of Cardiovascular Medicine, Saint Luke’s Mid America Heart Institute, Kansas, MO 45750, United States
Siva Naga S Yarrarapu, Department of Geriatric Medicine, University of Texas Health Science Center, San Antonio, TX 78249, United States
Harsimar Singh, Family Medicine, Ochsner Central Clinic, Baton Rouge, LA 70818, United States
Anureet Malhotra, Department of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE 68198, United States
Jennifer Schram, Mayo Clinic Libraries, Mayo Clinic Health System, Eau Claire, WI 54702, United States
Pankaj Bansal, Department of Rheumatology, Mayo Clinic College of Medicine, Eau Claire, WI 54702, United States
Pankaj Bansal, Department of Rheumatology, Orlando Arthritis and Rheumatology Clinic, Orlando, FL 32819, United States
Author contributions: Dalia T, Goyal A, Bansal P, and Shah Z contributed to the conceptualization, study design, literature screening, and data synthesis; Kohli V, Malhotra A, Mancuso J, and Yarrarapu SNS participated in data extraction; Yarrarapu SNS and Kohli V contributed to risk of bias assessment; Dalia T, and Singh H, created tables and drafted the manuscript; Shah Z and Bansal P, reviewed and edited the manuscript; Goyal A and Dalia T contributed to reference management; Schram J contributed to project administration; Kohli V and Bansal P contributed to statistical analysis; Shah Z and Dalia T contributed to overall supervision; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Zubair Shah, MD, Assistant Professor, Department of Cardiovascular Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas, KS 66160, United States. zshah2@kumc.edu
Received: February 9, 2026
Revised: March 20, 2026
Accepted: April 16, 2026
Published online: May 26, 2026
Processing time: 100 Days and 17.4 Hours
Revised: March 20, 2026
Accepted: April 16, 2026
Published online: May 26, 2026
Processing time: 100 Days and 17.4 Hours
Core Tip
Core Tip: We conducted systematic review and meta-analysis assessing prognostic tools in transthyretin amyloid cardiomyopathy (ATTR-CM) amyloidosis. Out of 7272 studies identified, 42 studies (13145 patients) were included. Prognostic factors associated with higher odds of mortality in transthyretin cardiomyopathy included: higher Gillmore staging, B type Natriuretic peptide, NT pro-BNP, troponin-T, interventricular septal thickness, New York heart association class. Prognostication of ATTR-CM patients can significantly aid in predicting disease severity and guide timely initiation of appropriate treatment strategies.